Potent TMEM16A Small Molecule Treatment for Inflammatory and Reactive Airway Diseases, Asthma, Hypertension, Pain and Cancer
- 技術優勢
- Transmembrane protein 16A (TMEM16A), also called anoctamin 1 (ANO1), is a Ca2+-activated Cl- channel expressed widely in mammalian epithelia, vascular smooth muscle and electrically excitable cells. Increased TMEM16A expression is associated with COPD and asthma, and TMEM16A is reported as a biomarker for gastrointestinal stromal and esophageal tumors. Pharmacological TMEM16A inhibitors, including the AACT small molecule scaffolds described in this invention, could be used to treat diseases such as inflammatory and reactive airway diseases, hypertension, gastrointestinal hypermotility and some cancers. The TMEM16A inhibitors developed by UCSF scientists have the following advantages: IC50 ~ 30 nM; substantially more potent than prior compoundsSubstantially better metabolic stability and PK than prior compoundsDemonstrated efficacy in acute hypertension, inhibition of intestinal smooth muscle contraction and inhibition of GI tumor cell growth
- 詳細技術說明
- The Verkman lab at the University of California, San Francisco has discovered, synthesized and biochemically evaluated of a series of TMEM16A inhibitors. The chemical structure of the 2-acylamino-cycloalkylthiophene-3-carboxylic acid arylamide inhibitor scaffold was refined through medicinal chemistry to identify bromodifluoroacetamide-based inhibitors with enhanced potency and metabolic stability.
- *Abstract
-
A novel class of 2-acylamino-cycloalkylthiophene-3-carboxylic acid arylamides (AACTs) as potent TMEM16A inhibitors
- *Principal Investigation
-
Name: Marc Anderson
Department:
Name: Puay-Wah Phuan
Department:
Name: Alan Verkman
Department:
- 其他
-
Stage of Development
Proof of Concept – in vitro and ex vivo
Looking for Partners
To develop & commercialize the TMEM16A inhibitors as therapies for inflammatory and reactive airway diseases, hypertension, gastrointestinal hypermotility and some cancers.
Data Availability
Under NCD/CDA
Related Materials
Additional Technologies by these Inventors
- CFTR potentiators and correctors and bifunctional (corrector/potentiator) compounds for treatment of Cystic Fibrosis
- SALT-SPARING UREA TRANSPORT INHIBITOR DIURETICS FOR TREATMENT OF CARDIOVASCULAR AND RENAL DISORDERS
- Immunotherapy for Treatment of Neuromyelitis Optica (NMO)
- Novel Small Molecule Drug for the Treatment of Constipation and Oxalate Kidney Stones
- Small Molecule Pendrin Inhibitors for Treatment of Inflammatory Airway Diseases and Diuretic Resistance
Tech ID/UC Case
29236/2017-138-0
Related Cases
2017-138-0
- 國家/地區
- 美國
欲了解更多信息，請點擊 這裡
